Ratings by H.C. Wainwright (Arthur He)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/3/2026 | Vera Therapeutics | VERA | Maintain | Buy (N/A) |
|
Details | ||
| 1/7/2026 | Jade Biosciences | JBIO | New Coverage | Buy (N/A) |
13.17 (14.05) |
6.68% | Details | |
| 12/17/2025 | Nektar Therapeutics | NKTR | Maintain | Buy (N/A) |
|
Details | ||
| 11/28/2025 | Vera Therapeutics | VERA | Maintain | Buy (Buy) |
|
Details | ||
| 11/10/2025 | Vera Therapeutics | VERA | Maintain | Buy (N/A) |
|
Details | ||
| 8/15/2025 | Adagene Inc | ADAG | Maintain | Buy (N/A) |
|
Details | ||
| 8/6/2025 | Lava Therapeutics NV | LVTX | Maintain | Neutral (N/A) |
|
Details | ||
| 7/30/2025 | Aurinia Pharmaceuticals | AUPH | New Coverage | Buy (N/A) |
8.95 (14.32) |
60% | Details | |
| 7/29/2025 | Adaptimmune Therapeutics plc | ADAP | Downgrade | Neutral (Buy) |
0.10 (0.05) |
-50% | Details | |
| 7/17/2025 | Prime Medicine | PRME | Maintain | Neutral (Neutral) |
|
Details | ||
| 6/25/2025 | Nektar Therapeutics | NKTR | Maintain | Buy (N/A) |
|
Details | ||
| 6/17/2025 | Solid Biosciences | SLDB | Maintain | Buy (Buy) |
|
Details | ||
| 6/9/2025 | Vera Therapeutics | VERA | Maintain | Buy (Buy) |
|
Details | ||
| 6/3/2025 | Vera Therapeutics | VERA | Maintain | Buy (N/A) |
|
Details | ||
| 5/20/2025 | Prime Medicine | PRME | Downgrade | Neutral (Buy) |
1.33 (4.01) |
201.5% | Details | |
| 5/12/2025 | Nektar Therapeutics | NKTR | Maintain | Buy (Buy) |
|
Details | ||
| 5/5/2025 | Vera Therapeutics | VERA | New Coverage | Buy (N/A) |
25.31 (39.07) |
54.37% | Details | |
| 4/1/2025 | Adaptimmune Therapeutics plc | ADAP | Maintain | Buy (N/A) |
|
Details | ||
| 3/19/2025 | Prime Medicine | PRME | Maintain | Buy (Buy) |
|
Details | ||
| 3/10/2025 | Solid Biosciences | SLDB | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2025 | Lava Therapeutics NV | LVTX | Downgrade | Neutral (Buy) |
1.35 (1.74) |
28.89% | Details | |
| 2/25/2025 | Nektar Therapeutics | NKTR | Maintain | Buy (Buy) |
|
Details | ||
| 1/27/2025 | Adagene Inc | ADAG | Maintain | Buy (N/A) |
|
Details | ||
| 12/20/2024 | Lava Therapeutics NV | LVTX | Maintain | Buy (N/A) |
|
Details | ||
| 12/10/2024 | Nektar Therapeutics | NKTR | New Coverage | Buy (N/A) |
1.01 (70.70) |
6900% | Details | |
| 11/14/2024 | Adaptimmune Therapeutics plc | ADAP | Maintain | Buy (N/A) |
|
Details | ||
| 11/13/2024 | BioAtla Inc. | BCAB | Downgrade | Neutral (Buy) |
2.19 (0.17) |
-92.24% | Details | |
| 10/2/2024 | Prime Medicine | PRME | Maintain | Buy (Buy) |
|
Details | ||
| 9/19/2024 | Adagene Inc | ADAG | Maintain | Buy (Buy) |
|
Details | ||
| 7/30/2024 | Adaptimmune Therapeutics plc | ADAP | New Coverage | Buy (N/A) |
1.37 (0.05) |
-96.35% | Details | |
| 6/28/2024 | Lava Therapeutics NV | LVTX | Maintain | Buy (Buy) |
|
Details | ||
| 5/28/2024 | Calliditas Therapeutics | CALT | Downgrade | Neutral (Buy) |
22.42 (40.00) |
78.41% | Details | |
| 5/24/2024 | Calliditas Therapeutics | CALT | Maintain | Buy (N/A) |
|
Details | ||
| 5/20/2024 | Prime Medicine | PRME | New Coverage | Buy (N/A) |
7.08 (4.01) |
-43.36% | Details | |
| 3/27/2024 | BioAtla Inc. | BCAB | Maintain | Buy (N/A) |
|
Details | ||
| 3/11/2024 | Solid Biosciences | SLDB | Maintain | Buy (N/A) |
|
Details | ||
| 12/8/2023 | Solid Biosciences | SLDB | New Coverage | Buy (N/A) |
5.76 (6.75) |
17.19% | Details | |
| 11/8/2023 | BioAtla Inc. | BCAB | Maintain | Buy (N/A) |
|
Details | ||
| 8/23/2023 | Lava Therapeutics NV | LVTX | Maintain | Buy (N/A) |
|
Details | ||
| 8/21/2023 | Calliditas Therapeutics | CALT | Maintain | Buy (N/A) |
|
Details | ||
| 6/20/2023 | Calliditas Therapeutics | CALT | New Coverage | Buy (N/A) |
18.45 (40.00) |
116.8% | Details | |
| 12/7/2022 | Adagene Inc | ADAG | New Coverage | Buy (N/A) |
1.11 (2.84) |
155.86% | Details | |
| 10/25/2022 | Lava Therapeutics NV | LVTX | New Coverage | Buy (N/A) |
4.26 (1.74) |
-59.15% | Details | |
| 8/10/2022 | BioAtla Inc. | BCAB | Maintain | Buy (N/A) |
|
Details | ||
| 3/21/2022 | BioAtla Inc. | BCAB | New Coverage | Buy (N/A) |
5.77 (0.17) |
-97.05% | Details |
